AAUM (Average Assets Under Management) of ₹5,369.64 Cr for Jul-Sep 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 64.9% | 65.9% | ▲ +1.0% |
| Healthcare Services | 27.6% | 25.6% | ▼ -2.0% |
| Chemicals & Petrochemicals | 2.3% | 2.2% | ▼ -0.2% |
| Healthcare Equipment & Supplies | 1.9% | 1.8% | ▼ -0.1% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 65.9% | 64.1% | ▼ -1.8% |
| Healthcare Services | 25.6% | 29.4% | ▲ +3.7% |
| Chemicals & Petrochemicals | 2.2% | 2.0% | ▼ -0.2% |
| Healthcare Equipment & Supplies | 1.8% | 1.5% | ▼ -0.3% |
Comparing Sep 2026 → Oct 2026
| # | Stock | Sector | Weight (Oct 2026) |
|---|---|---|---|
| 1 | Paras Healthcare Ltd. ₹151.30 Cr |
Healthcare Services | 2.49% |
| 2 | Manipal Health Enterprises Ltd ₹60.22 Cr |
Healthcare Services | 0.99% |
| 3 | Zydus Lifesciences Limited ₹28.58 Cr |
Pharmaceuticals & Biotechnology | 0.47% |
| # | Stock | Sector | Last Weight (Sep 2026) |
|---|---|---|---|
| 1 | Rainbow Childrens Medicare Limited ₹39.43 Cr |
Healthcare Services | 0.67% |
| # | Stock | Sector | Sep 2026 | Oct 2026 | Change |
|---|---|---|---|---|---|
| 1 | Max Healthcare Institute Limited ₹301.05 Cr |
Healthcare Services | 3.80% | 4.96% | +1.16% |
| 2 | Laurus Labs Limited ₹288.66 Cr |
Pharmaceuticals & Biotechnology | 4.05% | 4.76% | +0.71% |
| 3 | Divi's Laboratories Limited ₹508.56 Cr |
Pharmaceuticals & Biotechnology | 7.91% | 8.38% | +0.47% |
| 4 | Apollo Hospitals Enterprise Limited ₹295.17 Cr |
Healthcare Services | 4.45% | 4.87% | +0.42% |
| 5 | Krishna Institute Of Medical Sciences Limited ₹112.29 Cr |
Healthcare Services | 1.69% | 1.85% | +0.16% |
| 6 | Gland Pharma Limited ₹185.75 Cr |
Pharmaceuticals & Biotechnology | 2.96% | 3.06% | +0.10% |
| 7 | Syngene International Limited ₹72.49 Cr |
Healthcare Services | 1.12% | 1.19% | +0.07% |
| # | Stock | Sector | Sep 2026 | Oct 2026 | Change |
|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical Industries Limited ₹639.97 Cr |
Pharmaceuticals & Biotechnology | 11.14% | 10.55% | -0.59% |
| 2 | Mankind Pharma Limited ₹74.78 Cr |
Pharmaceuticals & Biotechnology | 1.71% | 1.23% | -0.48% |
| 3 | Sudeep Pharma Limited ₹145.29 Cr |
Pharmaceuticals & Biotechnology | 2.79% | 2.39% | -0.40% |
| 4 | Healthcare Global Enterprises Limited ₹81.98 Cr |
Healthcare Services | 1.70% | 1.35% | -0.35% |
| 5 | Aurobindo Pharma Limited ₹188.32 Cr |
Pharmaceuticals & Biotechnology | 3.42% | 3.10% | -0.32% |
| 6 | Torrent Pharmaceuticals Limited ₹249.12 Cr |
Pharmaceuticals & Biotechnology | 4.42% | 4.11% | -0.31% |
| 7 | Poly Medicure Limited ₹92.77 Cr |
Healthcare Equipment & Supplies | 1.82% | 1.53% | -0.29% |
| 8 | Concord Biotech Limited ₹119.58 Cr |
Pharmaceuticals & Biotechnology | 2.25% | 1.97% | -0.28% |
| 9 | Innova Captab Limited ₹85.44 Cr |
Pharmaceuticals & Biotechnology | 1.65% | 1.41% | -0.24% |
| 10 | Ajanta Pharma Limited ₹94.74 Cr |
Pharmaceuticals & Biotechnology | 1.79% | 1.56% | -0.23% |
37 stocks — Oct 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹639.97 Cr |
Pharmaceuticals & Biotechnology |
10.55%
|
|
| 2 |
₹508.56 Cr |
Pharmaceuticals & Biotechnology |
8.38%
|
|
| 3 |
₹301.05 Cr |
Healthcare Services |
4.96%
|
|
| 4 |
₹300.27 Cr |
Pharmaceuticals & Biotechnology |
4.95%
|
|
| 5 |
₹295.17 Cr |
Healthcare Services |
4.87%
|
|
| 6 |
₹288.66 Cr |
Pharmaceuticals & Biotechnology |
4.76%
|
|
| 7 |
₹264.75 Cr |
Pharmaceuticals & Biotechnology |
4.36%
|
|
| 8 |
₹249.12 Cr |
Pharmaceuticals & Biotechnology |
4.11%
|
|
| 9 |
₹188.32 Cr |
Pharmaceuticals & Biotechnology |
3.10%
|
|
| 10 |
₹185.75 Cr |
Pharmaceuticals & Biotechnology |
3.06%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.